Q3 2018 EPS Estimates for Fresenius Medical Care Corporation (FMS) Raised by Analyst

Fresenius Medical Care Corporation (NYSE:FMS) – Analysts at SunTrust Banks lifted their Q3 2018 earnings estimates for shares of Fresenius Medical Care Corporation in a note issued to investors on Wednesday. SunTrust Banks analyst D. Macdonald now anticipates that the company will post earnings per share of $0.66 for the quarter, up from their previous forecast of $0.65. SunTrust Banks also issued estimates for Fresenius Medical Care Corporation’s Q4 2018 earnings at $0.66 EPS, FY2018 earnings at $2.56 EPS, Q1 2019 earnings at $0.67 EPS and FY2019 earnings at $2.77 EPS.



WARNING: “Q3 2018 EPS Estimates for Fresenius Medical Care Corporation (FMS) Raised by Analyst” was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://ledgergazette.com/2017/11/18/q3-2018-eps-estimates-for-fresenius-medical-care-corporation-fms-raised-by-analyst.html.

A number of other research firms have also issued reports on FMS. Royal Bank Of Canada restated a “hold” rating and set a $44.00 price target on shares of Fresenius Medical Care Corporation in a report on Wednesday, September 13th. Zacks Investment Research lowered shares of Fresenius Medical Care Corporation from a “buy” rating to a “sell” rating in a report on Wednesday, October 25th. DZ Bank AG restated a “buy” rating on shares of Fresenius Medical Care Corporation in a report on Monday, August 7th. Finally, BidaskClub downgraded shares of Fresenius Medical Care Corporation from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $48.50.

Fresenius Medical Care Corporation (NYSE:FMS) traded down $0.32 during mid-day trading on Friday, hitting $48.83. 120,963 shares of the stock were exchanged, compared to its average volume of 182,549. Fresenius Medical Care Corporation has a twelve month low of $38.05 and a twelve month high of $50.22. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.22 and a quick ratio of 0.98. The firm has a market capitalization of $30,360.00, a price-to-earnings ratio of 22.05, a P/E/G ratio of 2.22 and a beta of 0.45.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Harding Loevner LP grew its position in Fresenius Medical Care Corporation by 4,271.1% during the third quarter. Harding Loevner LP now owns 163,837,558 shares of the company’s stock valued at $31,245,000 after purchasing an additional 160,089,385 shares in the last quarter. Cambiar Investors LLC grew its position in Fresenius Medical Care Corporation by 3.8% in the third quarter. Cambiar Investors LLC now owns 2,695,714 shares of the company’s stock worth $131,793,000 after acquiring an additional 99,234 shares in the last quarter. Royal Bank of Canada grew its position in Fresenius Medical Care Corporation by 6.4% in the second quarter. Royal Bank of Canada now owns 501,694 shares of the company’s stock worth $24,248,000 after acquiring an additional 30,119 shares in the last quarter. US Bancorp DE grew its position in Fresenius Medical Care Corporation by 10.4% in the second quarter. US Bancorp DE now owns 427,021 shares of the company’s stock worth $20,637,000 after acquiring an additional 40,121 shares in the last quarter. Finally, Parametric Portfolio Associates LLC grew its position in Fresenius Medical Care Corporation by 8.2% in the second quarter. Parametric Portfolio Associates LLC now owns 399,706 shares of the company’s stock worth $19,318,000 after acquiring an additional 30,140 shares in the last quarter. 2.62% of the stock is currently owned by hedge funds and other institutional investors.

Fresenius Medical Care Corporation Company Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Earnings History and Estimates for Fresenius Medical Care Corporation (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply